C Yee J A Thompson P Roche D R Byrd P P Lee M Piepkorn K Kenyon M M Davis S R Riddell P D Greenberg
10.1084/jem.192.11.1637
J Exp Med
2000 Dec 4;192(11):1637-44.
CC BY-NC-SA
https://pubmed.ncbi.nlm.nih.gov/11104805/
Antigens, Neoplasm / immunology Immunotherapy, Adoptive / adverse effects Melanocytes / immunology Melanoma / therapy Neoplasm Proteins / immunology Skin Neoplasms / therapy Vitiligo / immunology
Antigens, Neoplasm / immunology Immunotherapy, Adoptive / adverse effects Melanocytes / immunology Melanoma / therapy Neoplasm Proteins / immunology Skin Neoplasms / therapy Vitiligo / immunology Case Reports Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Antigens, Neoplasm / biosynthesis Female Humans Immunotherapy, Adoptive / methods MART-1 Antigen Melanocytes / cytology Melanoma / complications Melanoma / immunology Melanoma / pathology Middle Aged Neoplasm Proteins / biosynthesis Skin / cytology Skin / immunology Skin / pathology Skin Neoplasms / complications Skin Neoplasms / immunology Skin Neoplasms / pathology T-Lymphocytes, Cytotoxic / classification T-Lymphocytes, Cytotoxic / immunology Vitiligo / etiology Vitiligo / pathology Antigens, Neoplasm MART-1 Antigen MLANA protein, human Neoplasm Proteins
PMC2193107
11104805
Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo
2000